{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:14:49Z","timestamp":1776644089179,"version":"3.51.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.neuropharm.2010.10.026","type":"journal-article","created":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T04:13:08Z","timestamp":1288584788000},"page":"460-466","source":"Crossref","is-referenced-by-count":59,"title":["In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"60","author":[{"given":"R. Scott","family":"Bitner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Markosyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur L.","family":"Nikkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge D.","family":"Brioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2010.10.026_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev.pharmtox.42.082701.145401","article-title":"Molecular psychology: roles for the ERK MAP kinase cascade in memory","volume":"42","author":"Adams","year":"2002","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/302832a0","article-title":"Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor","volume":"302","author":"Arrang","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/exnr.2000.7397","article-title":"On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis","volume":"163","author":"Bartus","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib4","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1523\/JNEUROSCI.2444-07.2007","article-title":"Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1\/2 and CREB phosphorylation pathways","volume":"27","author":"Bitner","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.110.167213","article-title":"In vivo pharmacological characterization of a novel selective {alpha}7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer\u2019s disease","volume":"334","author":"Bitner","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainres.2009.01.069","article-title":"Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo","volume":"1265","author":"Bitner","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","article-title":"The many faces of CREB","volume":"28","author":"Carlezon","year":"2005","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neuropharm.2004.09.014","article-title":"Propentofylline attenuates tau hyperphosphorylation in Alzheimer\u2019s Swedish mutant model Tg2576","volume":"48","author":"Chauhan","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.neubiorev.2004.09.006","article-title":"Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates","volume":"28","author":"Dalley","year":"2004","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib30","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1523\/JNEUROSCI.21-12-04125.2001","article-title":"Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease","volume":"21","author":"Dineley","year":"2001","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib10","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjp.2008.147","article-title":"The histamine H3 receptor: an attractive target for the treatment of cognitive disorders","volume":"154","author":"Esbenshade","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.104.078303","article-title":"Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties","volume":"313","author":"Esbenshade","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.104.078402","volume":"313","author":"Fox","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib13","first-page":"257","article-title":"The H3 receptor antagonist clobenpropit protects against Abeta42-induced neurotoxicity in differentiated rat PC12 cells","volume":"65","author":"Fu","year":"2010","journal-title":"Pharmazie"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-2007-12105","article-title":"One hundred years after the discovery of Alzheimer\u2019s disease. A turning point for therapy?","volume":"12","author":"Giacobini","year":"2007","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib16","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuropharm.2005.09.017","article-title":"Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice","volume":"50","author":"Jia","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2010.07.012","article-title":"ADDLs and the signaling web that leads to Alzheimer\u2019s disease","author":"Krafft","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib20","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP","volume":"293","author":"Lewis","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.026_bib21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/78078","article-title":"Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein","volume":"25","author":"Lewis","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1471-4159.2007.04869.x","article-title":"Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer\u2019s models","volume":"103","author":"Ma","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib23","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1471-4159.2009.06249.x","article-title":"Activation of the histaminergic H3 receptor induces phosphorylation of the Akt\/GSK-3 beta pathway in cultured cortical neurons and protects against neurotoxic insults","volume":"110","author":"Mariottini","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/jpet.107.120311","article-title":"GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer\u2019s disease brain and improves cognitive performance in preclinical models","volume":"321","author":"Medhurst","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib25","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer\u2019s disease mouse model","volume":"29","author":"Puzzo","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/neu.20223","article-title":"Transcriptional profiling of brain-derived-neurotrophic factor-induced neuronal plasticity: a novel role for nociceptin in hippocampal neurite outgrowth","volume":"66","author":"Ring","year":"2006","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/ern.09.23","article-title":"Donepezil in the treatment of patients with Alzheimer\u2019s disease","volume":"9","author":"Tsuno","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib28","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1111\/j.1460-9568.2007.05905.x","article-title":"Restoration of impaired phosphorylation of cyclic AMP response element-binding protein (CREB) by EGb 761 and its constituents in Abeta-expressing neuroblastoma cells","volume":"26","author":"Xu","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.026_bib29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0006-8993(99)01220-2","article-title":"Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type","volume":"824","author":"Yamamoto-Sasaki","year":"1999","journal-title":"Brain Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810002960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810002960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T20:32:09Z","timestamp":1559766729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390810002960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":30,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0028390810002960"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2010.10.026","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}